Skip to content

Press Releases

Feb 23, 2021
ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third Quarter Over 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S. CLEAR Outcomes Study Design Highlighted in The American
Feb 09, 2021
Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Tuesday, February 23, 2021. Following the release, company management will host a webcast
Jan 29, 2021
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 28, 2021, the Compensation Committee of Esperion’s Board of Directors granted 10 new employees (i) non-qualified stock options to purchase an aggregate of 150,000 shares of its common stock,
Jan 13, 2021
ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million – – Range represents over 140 percent sequential growth for NEXLETOL ® (bempedoic acid) tablets and NEXLIZET ® (bempedoic acid and ezetimibe) tablets – – Company provides full-year 2021 operating expense guidance